MedreLeaf Corp. - new Licensed Producer - IPO

Zitat:"2017-06-07 09:07 Medreleaf completes IPO, secondary offering for $100.7M

About Medreleaf Corp. / Medreleaf is a

... (automatisch gekürzt) ...

https://www.stockwatch.com/News/...78625&symbol=LEAF&region=C

Zitat:" Medreleaf Corp. has closed its initial public offering and secondary offering pursuant to the final prospectus of Medreleaf dated May 30, 2017, and an underwriting agreement entered into among Medreleaf and certain selling shareholders, namely Zola Finance Inc., MENA Investment Network Inc., AJA Holdings 2013 Inc., Rayray Investments Inc., Tikun Olam Ltd., Baronford Heights Ltd., Eva Fashion Ltd., MedMen Opportunity Fund LP and Neil Closner, and GMP Securities LP as co-lead underwriter and sole bookrunner, Clarus Securities Inc. as co lead underwriter, Canaccord Genuity Corp., Cowen and Company LLC, Eight Capital, and PI Financial Corp....

Following a capital reorganization of Medreleaf that was completed prior to, and in connection with, the closing of the IPO and described in the Prospectus, immediately prior to the closing of the IPO, Zola Finance Inc. ("Zola") owned 15,525,404 Common Shares, representing approximately 19.0% of the issued and outstanding Common Shares...In connection with the IPO, Zola entered into a lock-up agreement with GMP pursuant to which Zola agreed, subject to certain exceptions, not to directly or indirectly offer, sell or otherwise dispose of, without the prior consent of GMP (on behalf of the Underwriters), any securities of Medreleaf for a period of: (a) 180 days following Closing, with respect to one-half of the securities of Medreleaf held by Zola;"ENDE Zitat

Source:www.stockwatch.com/News/...LEAF-2478802&symbol=LEAF®ion=C

Zitat:" Following a capital reorganization of Medreleaf that was completed prior to, and in connection with, the closing of the IPO and described in the Prospectus, immediately prior to the closing of the IPO, Raymond Leach owned and controlled, indirectly through Rayray Investments Inc. ("Rayray"), 12,509,479 Common Shares, representing approximately 15.3% of the issued and outstanding Common Shares......In connection with the closing of the IPO, Medreleaf issued and sold 8,494,742 Common Shares from treasury and the Selling Shareholders sold an aggregate of 2,105,258 Common Shares, of which 342,322 Common Shares were sold by Rayray, all at a price of $9.50 per Common Share (for gross proceeds to Rayray of $3,252,059). Immediately after the closing of the IPO, Raymond Leach owned and controlled, indirectly through Rayray, 12,167,157 Common Shares, representing approximately 13.5% of the issued and outstanding Common Shares... Except as set out in this press release, Raymond Leach intends to hold the Common Shares owned and controlled by him for investment purposes. Raymond Leach will evaluate his investment in Medreleaf from time to time and, except as provided herein, may, based on such evaluation, market conditions and other circumstances, acquire further Common Shares or other securities of Medreleaf or dispose of his holdings of securities of Medreleaf.....In connection with the IPO, Rayray entered into a lock-up agreement with GMP pursuant to which Rayray agreed, subject to certain exceptions, not to directly or indirectly offer, sell or otherwise dispose of, without the prior consent of GMP (on behalf of the Underwriters), any securities of Medreleaf for a period of: (a) 180 days following Closing, with respect to one-half of the securities of Medreleaf held by Rayray.."ENDE Zitat
Source:www.stockwatch.com/News/...LEAF-2478803&symbol=LEAF®ion=C

Zitat."Following a capital reorganization of Medreleaf that was completed prior to, and in connection with, the closing of the IPO and described in the Prospectus, immediately prior to the closing of the IPO, Tikun Olam Ltd. ("TO") owned 10,675,394 Common Shares, representing approximately 13.0% of the issued and outstanding Common Shares. The Common Shares owned by TO are controlled by Tsachi Cohen...Immediately after the closing of the IPO, TO owned 10,383,265 Common Shares, representing approximately 11.5% of the issued and outstanding Common Shares...In connection with the IPO, TO entered into a lock-up agreement with GMP pursuant to which TO agreed, subject to certain exceptions, not to directly or indirectly offer, sell or otherwise dispose of, without the prior consent of GMP (on behalf of the Underwriters), any securities of Medreleaf for a period of: (a) 180 days following Closing, with respect to one-half of the securities of Medreleaf held by TO.." ENDE Zitat
Source:www.stockwatch.com/News/...LEAF-2478805&symbol=LEAF®ion=C

Zitat:"Following a capital reorganization of Medreleaf that was completed prior to, and in connection with, the closing of the IPO and described in the Prospectus, immediately prior to the closing of the IPO, Stephen Arbib owned indirectly through AJA Holdings 2013 Inc. ("AJA") 6,254,629 Common Shares and controlled through MENA Investment Network Inc. ("MENA") 4,792,418 Common Shares, representing in aggregate approximately 13.5% of the issued and outstanding Common Shares....Immediately after the closing of the IPO, Stephen Arbib owned indirectly through AJA 6,083,470 Common Shares and controlled through MENA 4,661,275 Common Shares, representing in aggregate approximately 11.9% of the issued and outstanding Common Shares..." ENDE Zitat
Source:www.stockwatch.com/News/...LEAF-2478806&symbol=LEAF®ion=C

Zitat:"The Globe and Mail reports in its Thursday, June 8, edition that MedReleaf tumbled $2.10 to close Wednesday at $7.40 in its stock market debut amid concerns about lofty valuations in the sector. The Globe's Niall McGee writes that MedReleaf raised $80.7-million through a treasury offering of 8.5 million shares. 5i Research's Peter Hodson says: "It's mostly a sign of fatigue in the industry. The Cannabis Wheaton situation sort of highlighted some of the conflicts that can exist." Earlier in the week, royalty streaming company Cannabis Wheaton Income pulled the plug on an $80-million financing with independent investment banks Eight Capital and Canaccord Genuity Group after it was revealed employees for both dealers owned an 8-per-cent interest in the firm, raising concerns about a conflict of interest... " ENDE Zitat
Soruce:www.stockwatch.com/News/...78915&symbol=LEAF&region=C

Wie soll man einen neuen Wert vorstellen, wenn keine ISIN vergeben wurde und somit keine Zuordnung möglich ist,... und um dem ganzen noch die Krone aufzusetzen,... wird auch noch moderiert,....

Siehe hier:Moderation
Zeitpunkt: 08.06.17 16:09
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen

Hinweis für chinasky: Bitte kürzer zitieren.

Zitat:" MEDRELEAF CORP. COMPLETES INITIAL PUBLIC OFFERING
Medreleaf Corp. has closed its initial public offering and secondary offering of an aggregate of 10.6 million common shares of Medreleaf at a price of $9.50 per common share for aggregate gross proceeds of $100.7-million, with Medreleaf and certain shareholders receiving gross proceeds of $80,700,049 and $19,999,951, respectively....The common shares will commence trading on June 7, 2017, on the Toronto Stock Exchange under the symbol LEAF...
Pursuant to the offering, Medreleaf issued 8,494,742 offered shares from treasury. In addition, 2,105,258 offered shares were sold pursuant to a secondary offering by the selling shareholders. Medreleaf will not receive any proceeds from the secondary offering.
The offering was managed by a syndicate of underwriters, including GMP Securities LP as co-lead underwriter and sole bookrunner, Clarus Securities Inc. as co-lead underwriter, and including Canaccord Genuity Corp., Cowen and Company LLC, Eight Capital and PI Financial Corp..." ENDE Zitat

Source:www.stockwatch.com/News/...78625&symbol=LEAF&region=C

Zitat:" Initiating coverage: MedReleaf Corp. BUY- LEAF-TSX, June 14, 2017
Target: C$14.00
MedReleaf produces and sells medical cannabis in Canada. The company was
one of the early applicants with Health Canada, providing it with a first mover
advantage. MedReleaf’s profitability is impressive with trailing twelve months
EBITDA levels that exceed all of the other public peers combined. The
company’s products are well perceived by users enabling MedReleaf to
charge a premium price. This, combined with the lowest production costs in
the industry, explains the company’s high profitability......Proceeds from the IPO will be used to fund expansion at the Bradford facility......which is expected to quadruple MedReleaf’s capacity to 35,000kg annually.This is expected to support the company’s entrance in the recreational
market which, at $5b, is expected to be 10x larger than the medical market.
We are initiating coverage of LEAF with a BUY....." ENDE Zitat
Full Article/Source:www.stockhouse.com/companies/...bol=t.leaf&postid=26378981

Zitat:"MARKHAM, ON, June 16, 2017 /CNW/ - MedReleaf Corp. (TSX: LEAF), Canada's first and only ISO 9001 certified cannabis producer, today announced that it will hold a conference call to discuss its fourth quarter and fiscal year 2017 results on Wednesday, June 28, 2017 at 8:00 a.m. (ET). The call will be hosted by Neil Closner, Chief Executive Officer, and Igor Gimelshtein, Chief Financial Officer, followed by a question and answer period. MedReleaf will report its financial results in the morning prior to the call." ENDE Zitat

investors.medreleaf.com/press-releases/...e-Call/default.aspx

MedReleaf receives license amendment from Health Canada to commence sales at its Bradford Facility

www.tmxmoney.com/en/news/company_releases/...&filter=8242

Vorbörslich soeben rausgekommen!!